News
AstraZeneca will pay CSPC $100 million upfront, with potential for up to $1.92 billion in milestone payments. Airsupra Phase 3b trial shows significant reduction in severe asthma exacerbations.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback